AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02926066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2-hAADC
Description: Dosage form: Aqueous solution Dose(s): 2.37x10\^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10\^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect
Study NCT01187056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training programme
Description: 2 x 2 hours of training (workshops)
Study NCT03859908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML
Description: As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
Study NCT01899573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCinch® Ventriculoplasty System
Description: Percutaneous intervention for the treatment of functional mitral regurgitation
Study NCT01984840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Study NCT01187056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training programme
Description: 2 x 2 hours of training (workshops)
Study NCT04677738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. breve
Description: Probiotic capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve B-3 in the morning before breakfast for 12 weeks.
Study NCT04677738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
Study NCT02507609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular blockade
Description: TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation
Study NCT02507609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep neuromuscular blockade
Description: PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
Study NCT03572621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.~Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.~Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.~Session 3: Presentation of available treatments, start intracavernous injections.~Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.~Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid.
Study NCT03572621 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Collection of data concerning their sexuality
Description: Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).
Study NCT03572621 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Participation
Description: Participation in a therapeutic education day.
Study NCT04631848 — intervention group
Intervention type: DEVICE
Intervention: ULTRASCORE™ Focused Force PTA Balloon
Description: The device will be used for percutaneous transluminal angioplasty (PTA) to dilatate calcified stenoses in below the knee vessels
Study NCT02965430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AL-SENSE
Description: A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis
Study NCT03027349 — intervention group
Intervention type: OTHER
Intervention: No intervention are provided
Study NCT02578199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing and nutrition
Description: Motivational Interviewing and Nutritional Counseling
Study NCT00543387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
Study NCT02403115 — intervention group
Intervention type: OTHER
Intervention: Serum collection
Description: Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
Study NCT00543387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m\^2 Q12H during the first 2 days of each 21-day cycle.
Study NCT01063153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osmotic Release Methylphenidate
Description: During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
Study NCT02717052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-ketamine (Main study)
Description: Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)
Study NCT02717052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (S)-ketamine (Pilot II)
Description: Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes.
Study NCT02717052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R,S)-ketamine (Pilot II)
Description: Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes.
Study NCT02717052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
Study NCT02717052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study II: PET1
Description: \[11C\]DASB PET
Study NCT02717052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study II: PET2
Description: \[11C\]DASB PET
Study NCT02717052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Main Study: PET1
Description: \[11C\]DASB PET
Study NCT03261583 — intervention group
Intervention type: OTHER
Intervention: Thoracis Surgery - Common care
Description: Observational study. It is only a matter of collecting clinical data.
Study NCT02076412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium
Description: Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
Study NCT02717052 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Main Study: PET1
Description: \[11C\]DASB PET
Study NCT02076412 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo tablet PO bid (morning and evening)
Study NCT02431208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Participants will receive intravenous (IV) atezolizumab until loss of clinical benefit, withdrawal, or study end. Cohorts A to C will receive 1200 milligrams (mg) on Day 1 of each 21-day cycle. Cohorts D to F (combination with daratumumab) will receive 840 mg on Days 2 and 16 of Cycle 1 and on Days 1 and 15 of each 28-day cycle thereafter.
Study NCT02431208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Participants will receive intravenous (IV) atezolizumab until loss of clinical benefit, withdrawal, or study end. Cohorts A to C will receive 1200 milligrams (mg) on Day 1 of each 21-day cycle. Cohorts D to F (combination with daratumumab) will receive 840 mg on Days 2 and 16 of Cycle 1 and on Days 1 and 15 of each 28-day cycle thereafter.
Study NCT02431208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive 16 milligrams per kilogram (mg/kg) IV daratumumab until loss of clinical benefit, withdrawal, or study end. Treatment will be per the U.S. Package Insert and given on Days 1, 8, 15, 22 of Cycles 1 and 2; on Days 1 and 15 of Cycles 3 to 6; and on Day 1 of each 28-day cycle thereafter.
Study NCT02431208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Participants will receive 16 milligrams per kilogram (mg/kg) IV daratumumab until loss of clinical benefit, withdrawal, or study end. Treatment will be per the U.S. Package Insert and given on Days 1, 8, 15, 22 of Cycles 1 and 2; on Days 1 and 15 of Cycles 3 to 6; and on Day 1 of each 28-day cycle thereafter.
Study NCT01108614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
Study NCT02717052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Main Study: PET2
Description: \[11C\]DASB PET
Study NCT02717052 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Main Study: PET2
Description: \[11C\]DASB PET
Study NCT02717052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study I: PET1
Description: \[11C\]DASB PET
Study NCT02717052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study I: PET2
Description: \[11C\]DASB PET
Study NCT02717052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R,S)-ketamine (Pilot I)
Description: Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)
Study NCT02717052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R,S)-ketamine (Pilot III)
Description: Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50
Study NCT02717052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study III: PET1
Description: \[11C\]DASB PET
Study NCT02717052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILOT Study III: PET2
Description: \[11C\]DASB PET
Study NCT02431208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.
Study NCT02431208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
Study NCT03369977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioGlue Surgical Adhesive
Description: BioGlue (produced by CryoLife in Kennesaw, GA) is a surgical adhesive with two components respectively purified bovine serum albumin (BSA) and Glutaraldehyde (their proportions are 4:1). Crosslinked bonds (covalent bonds) of Glutaraldehyde cross-link the protein on the surface of the tissue and the amino residue of the bovine serum albumin. BioGlue also adheres to the synthetic matrix material by a mechanical interlocking mechanism in the space of graft matrix.
Study NCT03369977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Surgical Repair
Description: Traditional surgical repair as determined by the surgeon
Study NCT01559051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipoaspiration with Local anesthesia
Description: Patients undergo a liposuction under local Anethesia. The AD-SVF are then isolated and infused IV and by inhalation delivery.
Study NCT02200276 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza
Study NCT02761382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based psychological treatment
Study NCT02761382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-specific psychological treatment
Study NCT04178720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lehfilcon A contact lenses
Description: Investigational silicone hydrogel contact lenses
Study NCT04178720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses
Study NCT04178720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based system for cleaning and disinfecting silicone hydrogel contact lenses
Study NCT02998697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Ferrous sulfate 200 mg t.i.d for 90 days
Study NCT02998697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Lactose 200 mg t.i.d for 90 days
Study NCT03749889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100 g carbs
Description: Participants will be assigned a diet of 100g carbs max for the day
Study NCT03749889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MyPlate
Description: 40-65% of daily intake is from carbohydrates
Study NCT02749617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: 2.5 mg PO BID
Study NCT05491902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [C11] Leucine PET scan
Description: Each participant will receive an i.v. bolus of the PET radioligand, \[11C\]-Leucine (\<100 μg), for each scan. \[11C\]-Leucine is a PET radioligand has been used and studied clinically (17-23) at micro-doses (\<100 μg) with no adverse effects.
Study NCT05491902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [18F] Flutemetamol PET scan
Description: Each participant will receive an i.v. bolus of the PET radioligand, \[18F\]-Flutemetamol (\< 10 μg), for each scan.
Study NCT05491902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.
Study NCT04178720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based system for cleaning and disinfecting silicone hydrogel contact lenses
Study NCT04499625 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sinus floor elevation
Study NCT04499625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinus floor elevation using an ultrasonic device
Study NCT02137096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate
Description: Etoposide is one of three drugs used in the high-dose conditioning phase
Study NCT02137096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is one of the drugs used in the high-dose conditioning phase.
Study NCT02137096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide is one of the drugs used in the high-dose conditioning phase
Study NCT02137096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
Study NCT02705196 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delolimogene mupadenorepvec
Description: oncolytic virus encoding TMZ-CD40L and 4-1BBL
Study NCT02705196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: chemotherapy
Study NCT02705196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: chemotherapy
Study NCT02705196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: anti-PD-L1 antibody
Study NCT00513435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given PO
Study NCT00513435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02966561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer-based activity promotion
Description: The central components of the 2 x 45 minutes lasting pedometer-based physical activity behaviour change intervention BCI are the following behaviour change techniques (BCTs):~* Instruction on how, where and when to perform the behaviour~* Prompt goal setting for physical activity~* Prompt self-monitoring of behaviour~* Feedback on behaviour. Participants receive a pedometer and a booklet with a physical activity diary and associated information on the importance of goal setting and keeping a physical activity diary, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities.
Study NCT02966561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short patient education and exercise
Description: The central components of the 2 x 45 minutes lasting intervention are revisions of knowledge of the pulmonary rehabilitation (standard care) in combination with related exercises:~* Revision of knowledge on exercise recommendations~* Revision of knowledge on possibilities of self-regulation of endurance training exercise intensity with the rate of perceived exertion (BORG-Scale)~* Revision of self-regulation of endurance exercise intensity~* Revision of strengthening activities consistent with the exercise recommendations.~Participants receive a booklet with information on the rate of perceived exertion, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities.
Study NCT02966561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (Standard care)
Description: Standard care is an in-patient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention based on a patient assessment followed by a combination of patient-tailored therapies. PR lasts on average 25 days. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current COPD-guidelines; physical training (4-5 units/week endurance training \[45 min\] and 3 units/week of strength training \[45 min\] per week, 7 units/week whole body vibration muscle training/week); structured COPD-patient education (6 hours patient education COPD + 1 hour device training); respiratory physiotherapy in groups \[2-4 units/week with 45 min\]. PR is implemented by an interdisciplinary rehabilitation team.
Study NCT02966561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation (Standard care)
Description: Standard care is an in-patient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention based on a patient assessment followed by a combination of patient-tailored therapies. PR lasts on average 25 days. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current COPD-guidelines; physical training (4-5 units/week endurance training \[45 min\] and 3 units/week of strength training \[45 min\] per week, 7 units/week whole body vibration muscle training/week); structured COPD-patient education (6 hours patient education COPD + 1 hour device training); respiratory physiotherapy in groups \[2-4 units/week with 45 min\]. PR is implemented by an interdisciplinary rehabilitation team.
Study NCT00930930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV